JP7448527B2 - ヘテロ環式化合物 - Google Patents
ヘテロ環式化合物 Download PDFInfo
- Publication number
- JP7448527B2 JP7448527B2 JP2021512830A JP2021512830A JP7448527B2 JP 7448527 B2 JP7448527 B2 JP 7448527B2 JP 2021512830 A JP2021512830 A JP 2021512830A JP 2021512830 A JP2021512830 A JP 2021512830A JP 7448527 B2 JP7448527 B2 JP 7448527B2
- Authority
- JP
- Japan
- Prior art keywords
- ring
- optionally substituted
- compound
- halogen
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018167488 | 2018-09-07 | ||
| JP2018167488 | 2018-09-07 | ||
| PCT/JP2019/035233 WO2020050409A1 (en) | 2018-09-07 | 2019-09-06 | Heterocyclic compound |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021536482A JP2021536482A (ja) | 2021-12-27 |
| JPWO2020050409A5 JPWO2020050409A5 (https=) | 2022-09-14 |
| JP2021536482A5 JP2021536482A5 (https=) | 2022-09-14 |
| JP7448527B2 true JP7448527B2 (ja) | 2024-03-12 |
Family
ID=68063002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021512830A Active JP7448527B2 (ja) | 2018-09-07 | 2019-09-06 | ヘテロ環式化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11932657B2 (https=) |
| EP (1) | EP3847176A1 (https=) |
| JP (1) | JP7448527B2 (https=) |
| KR (1) | KR102810086B1 (https=) |
| CN (1) | CN112654627A (https=) |
| AU (2) | AU2019335968B2 (https=) |
| CA (1) | CA3109610A1 (https=) |
| EA (1) | EA202190654A1 (https=) |
| IL (1) | IL280821B2 (https=) |
| SG (1) | SG11202101963XA (https=) |
| TW (1) | TWI854995B (https=) |
| WO (1) | WO2020050409A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7448527B2 (ja) | 2018-09-07 | 2024-03-12 | 大塚製薬株式会社 | ヘテロ環式化合物 |
| IL291322B2 (en) | 2019-12-09 | 2026-02-01 | Otsuka Pharma Co Ltd | Acrylamide compounds |
| US20230279000A1 (en) | 2020-02-26 | 2023-09-07 | Jaguahr Therapeutics Pte Ltd | Pyridopyrimidine derivatives useful in modulation of ahr signalling |
| CN114181212B (zh) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | 哒嗪酮类AhR抑制剂 |
| CN115215720B (zh) * | 2021-04-19 | 2023-08-22 | 中国科学院化学研究所 | 含薁单元的石墨烯纳米片段分子—薁并玉红省及其合成方法与应用 |
| WO2022228399A1 (zh) * | 2021-04-27 | 2022-11-03 | 山东轩竹医药科技有限公司 | 三并环类usp1抑制剂及其用途 |
| WO2023033742A1 (en) * | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| KR20240054994A (ko) * | 2021-09-02 | 2024-04-26 | 재규어 테라퓨틱스 피티이 리미티드 | AhR 시그널링의 조절에 유용한 화합물 |
| WO2023033741A1 (en) * | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| WO2024076300A1 (en) | 2022-10-03 | 2024-04-11 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| JP7527515B1 (ja) * | 2022-10-29 | 2024-08-02 | 松本油脂製薬株式会社 | 弾性繊維用処理剤及びその利用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012082997A1 (en) | 2010-12-16 | 2012-06-21 | F. Hoffmann-La-Roche Ag | Tricyclic pi3k inhibitor compounds and methods of use |
| WO2014138485A1 (en) | 2013-03-08 | 2014-09-12 | Irm Llc | Ex vivo production of platelets from hematopoietic stem cells and the product thereof |
| WO2016204256A1 (ja) | 2015-06-16 | 2016-12-22 | 国立大学法人京都大学 | 高機能性血小板の製造方法 |
| WO2018195397A2 (en) | 2017-04-21 | 2018-10-25 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| WO2019167973A1 (en) | 2018-03-01 | 2019-09-06 | Kyoto University | Cell cycle progression inhibitor |
| JP7448527B2 (ja) | 2018-09-07 | 2024-03-12 | 大塚製薬株式会社 | ヘテロ環式化合物 |
| IL291322B2 (en) | 2019-12-09 | 2026-02-01 | Otsuka Pharma Co Ltd | Acrylamide compounds |
| JP2022188761A (ja) | 2021-06-09 | 2022-12-21 | 大塚製薬株式会社 | 窒素原子含有複素環化合物を用いる血小板産生方法 |
-
2019
- 2019-09-06 JP JP2021512830A patent/JP7448527B2/ja active Active
- 2019-09-06 CN CN201980058108.7A patent/CN112654627A/zh active Pending
- 2019-09-06 EP EP19773956.8A patent/EP3847176A1/en active Pending
- 2019-09-06 KR KR1020217009658A patent/KR102810086B1/ko active Active
- 2019-09-06 SG SG11202101963XA patent/SG11202101963XA/en unknown
- 2019-09-06 EA EA202190654A patent/EA202190654A1/ru unknown
- 2019-09-06 US US17/271,479 patent/US11932657B2/en active Active
- 2019-09-06 TW TW108132216A patent/TWI854995B/zh active
- 2019-09-06 IL IL280821A patent/IL280821B2/en unknown
- 2019-09-06 WO PCT/JP2019/035233 patent/WO2020050409A1/en not_active Ceased
- 2019-09-06 CA CA3109610A patent/CA3109610A1/en active Pending
- 2019-09-06 AU AU2019335968A patent/AU2019335968B2/en active Active
-
2024
- 2024-01-18 US US18/416,261 patent/US20240208999A1/en active Pending
- 2024-06-04 AU AU2024203760A patent/AU2024203760A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012082997A1 (en) | 2010-12-16 | 2012-06-21 | F. Hoffmann-La-Roche Ag | Tricyclic pi3k inhibitor compounds and methods of use |
| WO2014138485A1 (en) | 2013-03-08 | 2014-09-12 | Irm Llc | Ex vivo production of platelets from hematopoietic stem cells and the product thereof |
| WO2016204256A1 (ja) | 2015-06-16 | 2016-12-22 | 国立大学法人京都大学 | 高機能性血小板の製造方法 |
| WO2018195397A2 (en) | 2017-04-21 | 2018-10-25 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
Non-Patent Citations (1)
| Title |
|---|
| Science，2014年，Vol. 345, No. 6203，p. 1509-1512 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019335968A1 (en) | 2021-05-06 |
| US20210340157A1 (en) | 2021-11-04 |
| CN112654627A (zh) | 2021-04-13 |
| WO2020050409A1 (en) | 2020-03-12 |
| CA3109610A1 (en) | 2020-03-12 |
| IL280821B1 (en) | 2024-10-01 |
| EA202190654A1 (ru) | 2021-05-27 |
| KR102810086B1 (ko) | 2025-05-21 |
| IL280821B2 (en) | 2025-02-01 |
| US11932657B2 (en) | 2024-03-19 |
| SG11202101963XA (en) | 2021-03-30 |
| NZ774547A (en) | 2025-10-31 |
| EP3847176A1 (en) | 2021-07-14 |
| US20240208999A1 (en) | 2024-06-27 |
| TW202035423A (zh) | 2020-10-01 |
| TWI854995B (zh) | 2024-09-11 |
| JP2021536482A (ja) | 2021-12-27 |
| AU2024203760A1 (en) | 2024-06-20 |
| KR20210056373A (ko) | 2021-05-18 |
| IL280821A (en) | 2021-04-29 |
| AU2019335968B2 (en) | 2024-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7448527B2 (ja) | ヘテロ環式化合物 | |
| TWI801372B (zh) | 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法 | |
| CA2793856C (en) | Tetrahydrobenzothiophene compound | |
| TWI836960B (zh) | 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法 | |
| KR20120034607A (ko) | 이미다조〔2,1-ｂ〕〔1,3,4〕티아디아졸 유도체 | |
| JP2025524674A (ja) | 新規のイソキノリノン、ピロロピリジノンおよびチエノピリジノンスルホンアミド誘導体 | |
| CN113666853B (zh) | 可用作RORγ调节剂的联芳基类化合物 | |
| JP5424187B2 (ja) | アシルアミノフェニル基を有する抗がん剤 | |
| JP7657800B2 (ja) | アクリルアミド化合物 | |
| HK40048052A (zh) | 杂环化合物 | |
| EA046483B1 (ru) | Гетероциклическое соединение | |
| HK40086122A (en) | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers | |
| HK40059281A (en) | BIARYL COMPOUNDS USEFUL AS RORγMODULATORS | |
| HK40019115B (en) | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers | |
| HK40019115A (en) | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220902 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220902 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231010 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231205 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240213 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240229 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7448527 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |